Dogma Therapeutics LLC, of Cambridge, Mass., disclosed an oral PCSK9 inhibitor program. In dyslipidemic nonhuman primates, multiple Dogma inhibitors produced significant and robust lowering of LDL cholesterol following multiple weeks of administration.